Bespoke Research on China and neighbouring regions, Bixmoor

Bixmoor

Bespoke Research on China and neighbouring regions

Bixmoor specialises in providing bespoke research to business, governments and the financial community on China and neighbouring regions. We seek to build long-term relationships with our clients, based on our expertise, our reliability and our determination to find the right solution.

Thematic (Sector/Industry)

<div>
China’s state media reported this week that Han Chunyu’s scientific results on genome editing which were published in Nature Biotechnology in May have been <a href="http://www.globaltimes.cn/content/997584.shtml" target="_blank">widely criticized</a> internationally. Han Chunyu was the “<a href="http://www.scmp.com/news/china/policies-politics/article/1947214/rise-underdogs-why-low-funded-unknown-researchers-are" target="_blank">nobody scientist</a>” in Hebei of whom no one had heard and was not practicing at prestigious Peking or Tsinghua Universities.
Almost all the overseas scientists criticized the Han Chunyu science, with the apparent exception of MIT. The feedback came from Australia, the USA and elsewhere.
On…
</div>


China’s state media reported this week that Han Chunyu’s scientific results on genome editing which were published in Nature Biotechnology in May have been widely criticized internationally. Han Chunyu was the “nobody scientist” in Hebei of whom no one had heard and was not practicing at prestigious Peking or Tsinghua Universities.
Almost all the overseas scientists criticized the Han Chunyu science, with the apparent exception of MIT. The feedback came from Australia, the USA and elsewhere.
On…


Senior Chinese officials regularly make all the appropriate noises about the evils of illicit drug use in China, but they seem unable to do anything about the massive drug manufacturing operations that take place almost openly in Guangdong province.

Senior Chinese officials regularly make all the appropriate noises about the evils of illicit drug use in China, but they seem unable to do anything about the massive drug manufacturing operations that take place almost openly in Guangdong province.

Breastfeeding rates in China are important, both in terms of stocks and for the health of the country. But how can we trust official statistics from a state agency that appear to contradict each other?

Breastfeeding rates in China are important, both in terms of stocks and for the health of the country. But how can we trust official statistics from a state agency that appear to contradict each other?

Chinese people are actively choosing not to have further children and this will lead inexorably to a population collapse during the balance of this century – a situation not helped by the fact that the state is still damaging its own overdue initiatives with retrogressive “family planning” strategies.

Chinese people are actively choosing not to have further children and this will lead inexorably to a population collapse during the balance of this century – a situation not helped by the fact that the state is still damaging its own overdue initiatives with retrogressive “family planning” strategies. 

Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

What will China look like in 2025? This is a follow up to our <a href="https://www.smartkarma.com/insights/outlook-for-china-10-predictions-for-the-next-10-years" target="_blank" data-smartkarma-citation="insights:2955">Outlook for China:10 Predictions for the Next 10 Years</a> presentation, where we present 10 key data visualisations to back up 10 bold predictions we expect to play out in China over the next 10 years.In this note we provide more background to the thinking behind our predictions.Analyst: Daniel Rohr, CFAChina's faltering economy has sent shivers through the global markets in 2016, and for good reason.As the world's second-largest economy…

What will China look like in 2025? This is a follow up to our Outlook for China:10 Predictions for the Next 10 Years presentation, where we present 10 key data visualisations to back up 10 bold predictions we expect to play out in China over the next 10 years.In this note we provide more background to the thinking behind our predictions.Analyst: Daniel Rohr, CFAChina's faltering economy has sent shivers through the global markets in 2016, and for good reason.As the world's second-largest economy…

China

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a major Chinese pharmaceutical firm engaged in the research, development, manufacturing, and sales of traditional Chinese medicines, Western pharmaceuticals, chemical raw materials, and health products. The company operates across segments including Great Southern Traditional Chinese Medicine, Great Health, Great Commerce, and Great Medical. It was founded on September 1, 1997, and is headquartered in Guangzhou, China.

Guangzhou Baiyunshan Pharmaceutical (874 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Guangzhou Baiyunshan Pharmaceutical (874 HK)

Critique of Genome Scientific Work

China’s state media reported this week that Han Chunyu’s scientific results on genome editing which were published in Nature Biotechnology in May...

Bixmoor

China's Disconnect on Illegal Drugs

Senior Chinese officials regularly make all the appropriate noises about the evils of illicit drug use in China, but they seem unable to do...

Bixmoor

Contradictory Stats on Breastfeeding

Breastfeeding rates in China are important, both in terms of stocks and for the health of the country. But how can we trust official statistics...

Bixmoor

Chinese Choose Not to Have More Children

Chinese people are actively choosing not to have further children and this will lead inexorably to a population collapse during the balance of this...

Bixmoor

What Will China Look Like in 2025?

What will China look like in 2025? This is a follow up to our Outlook for China:10 Predictions for the Next 10 Years presentation, where we present...

Morningstar, Inc.

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)